SCOPUS 정보 검색 플랫폼

Rheumatology International

Volumn 31, Issue 4, 2011, Pages 481-484

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis

(3) Mishra, Richa a Singh, Vijay b Pritchard, Charles H c

a UNIVERSITY OF PENNSYLVANIA (United States)

b DREXEL UNIVERSITY COLLEGE OF MEDICINE (United States)

c Rheumatic Disease Associates (United States)

Author keywords

B cell; Biologic therapy; Rheumatoid arthritis; Rituximab; Safety

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; RITUXIMAB;

ADULT; ARTICLE; ASEPTIC MENINGITIS; CARBUNCLE; CELLULITIS; CLINICAL ARTICLE; DISEASE DURATION; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLOW UP; HERPES ZOSTER; HOSPITALIZATION; HUMAN; MALE; MEDICAL RECORD REVIEW; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 79954443732 PISSN: 01728172 EISSN: None Source Type: Journal
DOI: 10.1007/s00296-009-1307-7 Document Type: Article

Times cited : (11)

References (12)

1
- 1442352158
- Epidemiology and Burden of Illness of Rheumatoid Arthritis
- TK Kvien 2004 Epidemiology and burden of illness of rheumatoid arthritis Pharmacoeconomics 22 Suppl. 2 1 12 15157000 (Pubitemid 38269929)
- (2004) PharmacoEconomics , vol.22 , Issue.2 SUPPL. , pp. 1-12
- Kvien, T.K.¹

2
- 1042290332
- Once-Weekly Administration of 50 mg Etanercept in Patients with Active Rheumatoid Arthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
- DOI 10.1002/art.20019
- EC Keystone MH Schiff JM Kremer S Kafka M Lovy T DeVries DJ Burge 2004 Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 50 353 363 14872476 10.1002/art.20019 1:CAS:528:DC%2BD2cXhvFeitLc%3D (Pubitemid 38198818)
- (2004) Arthritis and Rheumatism , vol.50 , Issue.2 , pp. 353-363
- Keystone, E.C.¹ Schiff, M.H.² Kremer, J.M.³ Kafka, S.⁴ Lovy, M.⁵ De Vries, T.⁶ Burge, D.J.⁷

3
- 0034735842
- Infliximab and methotrexate in the treatment of rheumatoid arthritis
- DOI 10.1056/NEJM200011303432202
- PE Lipsky DM van der Heijde EW St Clair, et al. 2000 Infliximab and methotrexate in the treatment of rheumatoid arthritis N Engl J Med 343 1594 1602 11096166 10.1056/NEJM200011303432202 1:CAS:528:DC%2BD3cXovVeltLk%3D (Pubitemid 32162982)
- (2000) New England Journal of Medicine , vol.343 , Issue.22 , pp. 1594-1602
- Lipsky, P.E.¹ Van Der Heijde, D.M.F.M.² St. Clair, E.W.³ Furst, D.E.⁴ Breedveld, F.C.⁵ Kalden, J.R.⁶ Smolen, J.S.⁷ Weisman, M.⁸ Emery, P.⁹ Feldmann, M.¹⁰ Harriman, G.R.¹¹ Maini, R.N.¹²

4
- 0037231533
- Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
- DOI 10.1002/art.10697
- ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara LA Teoh SA Fischkoff EK Chartash 2003 Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 48 35 45 12528101 10.1002/art.10697 1:CAS:528:DC%2BD3sXhtFGnsb0%3D (Pubitemid 36091645)
- (2003) Arthritis and Rheumatism , vol.48 , Issue.1 , pp. 35-45
- Weinblatt, M.E.¹ Keystone, E.C.² Furst, D.E.³ Moreland, L.W.⁴ Weisman, M.H.⁵ Birbara, C.A.⁶ Teoh, L.A.⁷ Fischkoff, S.A.⁸ Chartash, E.K.⁹

5
- 37249092920
- The potential utility of B cell-directed biologic therapy in autoimmune diseases
- 17957371 10.1007/s00296-007-0471-x
- DG Arkfeld 2007 The potential utility of B cell-directed biologic therapy in autoimmune diseases Rheumatol Int 28 205 215 17957371 10.1007/s00296-007- 0471-x
- (2007) Rheumatol Int , vol.28 , pp. 205-215
- Arkfeld, D.G.¹

6
- 33646342760
- B cell-targeted therapy for rheumatoid arthritis: An update on the evidence
- DOI 10.2165/00003495-200666050-00004
- RJ Looney 2006 B cell-targeted therapy for rheumatoid arthritis: an update on the evidence Drugs 66 625 639 16620141 10.2165/00003495-200666050- 00004 1:CAS:528:DC%2BD28XlsVCisbk%3D (Pubitemid 43671455)
- (2006) Drugs , vol.66 , Issue.5 , pp. 625-639
- Looney, R.J.¹

7
- 34047142747
- Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs
- DOI 10.1093/rheumatology/kel393
- C Popa MJ Leandro G Cambridge JC Edwards 2007 Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs Rheumatology (Oxford) 46 626 630 10.1093/rheumatology/kel393 1:CAS:528:DC%2BD2sXjslOnt7o%3D (Pubitemid 46523308)
- (2007) Rheumatology , vol.46 , Issue.4 , pp. 626-630
- Popa, C.¹ Leandro, M.J.² Cambridge, G.³ Edwards, J.C.W.⁴

8
- 38149138097
- The effects of rituximab on immunocompetency in patients with autoimmune disease
- 18163518 10.1002/art.23171 1:CAS:528:DC%2BD1cXhslOjsLc%3D
- RJ Looney R Srinivasan LH Calabrese 2008 The effects of rituximab on immunocompetency in patients with autoimmune disease Arthritis Rheum 58 5 14 18163518 10.1002/art.23171 1:CAS:528:DC%2BD1cXhslOjsLc%3D
- (2008) Arthritis Rheum , vol.58 , pp. 5-14
- Looney, R.J.¹ Srinivasan, R.² Calabrese, L.H.³

9
- 55949083111
- Tumor necrosis factor inhibitors and infection complications
- 18817643 10.1007/s11926-008-0062-1 1:CAS:528:DC%2BD1MXitFWms7o%3D
- M Crawford JR Curtis 2008 Tumor necrosis factor inhibitors and infection complications Curr Rheumatol Rep 10 383 389 18817643 10.1007/s11926-008-0062-1 1:CAS:528:DC%2BD1MXitFWms7o%3D
- (2008) Curr Rheumatol Rep , vol.10 , pp. 383-389
- Crawford, M.¹ Curtis, J.R.²

10
- 33748444790
- Problems encountered during anti-tumour necrosis factor therapy
- DOI 10.1016/j.berh.2006.06.002, PII S1521694206000726
- SB Desai DE Furst 2006 Problems encountered during anti-tumour necrosis factor therapy Best Pract Res Clin Rheumatol 20 757 790 16979537 10.1016/j.berh.2006.06.002 1:CAS:528:DC%2BD28Xps1Cntb8%3D (Pubitemid 44350122)
- (2006) Best Practice and Research: Clinical Rheumatology , vol.20 , Issue.4 , pp. 757-790
- Desai, S.B.¹ Furst, D.E.²

11
- 36448972397
- Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis
- 17977488 1:STN:280:DC%2BD2snosV2qsw%3D%3D
- J Sibilia R Westhovens 2007 Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis Clin Exp Rheumatol 25 Suppl 46 S46 S56 17977488 1:STN:280:DC%2BD2snosV2qsw%3D%3D
- (2007) Clin Exp Rheumatol , vol.25 , Issue.SUPPL. 46
- Sibilia, J.¹ Westhovens, R.²

12
- 67651120559
- Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients
- Jan 20 [Epub ahead of print]
- Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, Baptiste Y, Chai A, Burke L, Reiss W, Sweetser M, Shaw TM (2009) Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009 Jan 20 [Epub ahead of print]
- (2009) Ann Rheum Dis 2009
- Genovese, M.C.¹ Breedveld, F.C.² Emery, P.³ Cohen, S.⁴ Keystone, E.⁵ Matteson, E.L.⁶ Baptiste, Y.⁷ Chai, A.⁸ Burke, L.⁹ Reiss, W.¹⁰ Sweetser, M.¹¹ Shaw, T.M.¹²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.